People are known to have resistant hypertension (RH) if their blood pressure (BP) does not reach the target despite being on ≥3 antihypertensive drugs of different classes at optimal doses, one of which being a diuretic. [1] [2] [3] Although the exact prevalence is unknown, 10%-30% of hypertensive patients have shown to have RH. [4] [5] [6] A previous study showed that RH resulted in poor cardiovascular outcomes compared to non-RH patients. 7 As uncontrolled BP increases the risk of heart disease, stroke, and renal failure, optimum BP control is a key for better cardiovascular outcomes. 8 To achieve optimum BP control, the addition of aldosterone antagonists (AA) has been shown to be an effective treatment in prior randomized controlled trials and observational studies. 4, 5 To better define the safety and efficacy of AA in patients with RH, we performed a meta-analysis of all randomized controlled trials and observational studies.
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METHODS

Data sources and search strategy
We wrote a study protocol in accordance with the PRISMA and MOOSE statements in-priori. 9, 10 We searched MEDLINE, EMBASE, and Cochrane CENTRAL Register for Clinical Trials for English-language publications from inception through March, 2014 with search terms "aldosterone antagonists" OR "spironolactone" OR "eplerenone" AND "resistant hypertension" OR "hypertension". Two authors (K.D. and S.K.) independently performed the database search and disagreement was resolved by consensus. A manual search was performed for all relevant references from selected articles and reviews.
Study selection
The algorithm for study selection is shown in Figure 1 . Comparative studies (both randomized and nonrandomized) and single-arm studies of AA in adult patients (≥18 years) with RH were selected for meta-analysis. Meeting abstracts, non-English language publications, and studies with pediatric patients or animals were excluded.
Data extraction
Two authors (K.D. and S.K.) extracted data from the selected studies in duplicate using standardized data extraction form. We obtained data on study characteristics (study design, follow-up duration, and number of patients), patient characteristics (age, sex, body mass index, baseline systolic BP [SBP] and diastolic BP [DBP] , and biochemical profile), type and dosage of AA used, number of antihypertensive agents, and various efficacy and safety outcomes as described below.
Outcomes
Change in office BP (both systolic and diastolic) was the primary outcome. The secondary outcomes were change in ambulatory BP (ABPM), effects on biochemical profile, change in the number of antihypertensive agents, and adverse events including hyperkalemia and gynecomastia/breast tenderness.
Statistical analysis
We performed separate analyses for comparative (randomized and nonrandomized) and single-arm studies. We pooled the continuous variables as mean difference and the categorical variables as risk ratio both with 95% confidence interval (CI) using DerSimonian-Laird random-effects model. We used crude events from each study to compute risk ratio with 95% CI when appropriate. The P <0.05 (2-tailed) was considered statistically significant. We examined the publication bias at the outcome level with Begg's funnel plot. We used Jadad scale with score from 1 to 5 to assess the quality of randomized studies based on randomization, blinding and withdrawals, and dropouts of participants. 11 
RESULTS
Description of included studies
After removal of duplicates, we assessed 521 citations for eligibility with 53 full-text review. A total of 17 studies 4, 5, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] were included in qualitative review and 15 (3 randomized 13 and 2 studies 16,21 used both eplerenone and spironolactone. The duration of follow-up was between 1.4 and 10.3 months. The doses of spironolactone and eplerenone were 12.5-100 mg and 50-100 mg, respectively. The individual study and patient characteristics are shown respectively in Tables 1 and 2 .
Primary outcome: office BP
The meta-analysis of comparative studies showed significant improvement in office BP ( Figure 1 ). When compared with placebo, AA reduced the SBP by 24.26 mm Hg (95% CI: 8.65-39.87, P = 0.002, I2: 95%) and DBP by 7.79 mm Hg (3.79-11.79, P = 0.0001, I2: 80%). Sensitivity analyses performed after removal of nonrandomized studies did not change the significant heterogeneity.
In meta-analysis of single-arm studies (Figure 2 ), AA caused significant reduction in SBP by 22.74 mm Hg (18.21-27.27, P < 0.00001, I2: 96%) and DBP by 10.49 mm Hg (8.85-12.13, P < 0.00001, I2: 76%). When analysis was only restricted to spironolactone (figure not shown), the reduction in SBP and DBP were, respectively, by 23.18 mm Hg (18.44-27.92, I2: 96%) and 10.74 mm Hg (9.07-12.4, I2: 75%).
Secondary outcomes
Ambulatory BP. In meta-analysis of comparative studies (Figure 2) , AA compared to placebo resulted in significant reduction in 24-hour ABPM (systolic) by 9.32 mm Hg (6.2-12.44, P < 0.00001, I2: 0%) and diastolic by 2.57 mm Hg (−0.27-5.4, P = 0.08, I2: 62%). Similarly, it reduced day ABPM (systolic) by 7.31 mm Hg (3.9-10.73, P < 0.0001, I2: 20%) and showed a trend towards reduction in day ABPM (diastolic) by 2.45 mm Hg (−0.008-4.98, P = 0.06, I2: 41%). Night ABPM (systolic and diastolic) were lower by 9.29 mm Hg (4.98-13.59, P < 0.0001, I2: 0%) and 3.11 mm Hg (0.47-5.76, P = 0.02, I2: 0%), respectively.
Meta-analysis of single-arm studies ( Figure 3 ) also showed significant reduction in 24-hour ABPM (systolic) by 16.52 mm Hg (12.47-20.57, P < 0.00001, I2: 65%) and diastolic by 8.04 mm Hg (6.21-9.86, P < 0.00001, I2: 60%).
Effect on biochemical profile. Meta-analysis of comparative studies did not result in significant change in serum sodium, potassium, and creatinine levels compared to placebo ( Figure 4 ). The change in serum sodium level was −0.33 (−2.89 to 2.22, P = 0.80, I: 67%), potassium 0.15 (−0.07 to 0.37, P = 0.19, I2: 18%), and creatinine −0.27 (−0.62 to 0.08, P = 0.13, I2: 0%).
On the other hand, AA resulted in significant change in biochemical parameters ( Figure 5 ) in single-arm studies. It reduced serum sodium level by −0.99 (−1.16, −0.82, P < 0.00001, I2: 0%), increased potassium level by 0.46 (0.37-0.54, P < 0.00001, I2: 63%), increased serum creatinine level by 0.11 (0.08-0.14, P < 0.00001, I2: 26%), and reduced glomerular filtration rate by −7.37 (−9.85, −4.9, P < 0.00001, I2: 0%).
Hyperkalemia and gynecomastia/breast tenderness. AA did not increase the risks of hyperkalemia compared to placebo (risk ratio: 2.93, 95% CI: 0.47-18.08, P = 0.25, I2: 0%) in comparative studies (Supplementary Figure 1) . However, the studies did not report any events of gynecomastia, breast tenderness, and libido reduction. In the study by Oxlund et al., 2 patients stopped taking medication compared to none in placebo. 24 Two studies reported no adverse events of gynecomastia, breast tenderness, or loss of libido in either arm. 5, 18 In meta-analysis of single-arm studies, AA increased the risks of hyperkalemia (Supplementary Figure 2) by 0.046 (0.043-0.105, P < 0.00001, I2: 72%) and gynecomastia/ breast tenderness (Supplementary Figure 3) by 0.064 (0.026-0.149, P < 0.00001, I2: 73%). Three studies did not report on adverse events. 12, 14, 25 Change in the number of antihypertensive agents. Only 4 studies [13] [14] [15] [16] reported on this outcome as mean (Supplementary Figure 4) . The AA did not result in the significant change in the total number of antihypertensive agents after therapy (mean change: 0.20 [−0.12 to 0.52], P = 0.22, I2: 55%).
Study quality and publication bias
The study quality of randomized studies was evaluated with Jadad scale of 1-5. One study 18 had a score of 1, another study 24 had 4, and the other study 5 had 5. Publication bias was visually examined with the help of funnel plot that was symmetrical for effects on biochemical profile and BP (single arm). Asymmetry was observed for meta-analysis of BP in comparative studies. Publication bias was further tested with Egger's regression intercept and Begg and Mazumdar rank correlation.
DISCUSSION
In the current meta-analysis, AA resulted in significant reduction in office and ABPM. Similarly, AA resulted in significant change in biochemical parameters in single-arm studies but not in comparative studies. In comparative studies, AA did not increase the risks of hyperkalemia whereas in single-arm studies, the risks of hyperkalemia and gynecomastia and breast tenderness were higher.
The NICE (National Institute for Health and Care Excellence) guidelines on the management of primary hypertension in adults recommends adding an AA in patients with RH when carefully monitoring for hyperkalemia, more so in the patients with chronic kidney disease. 27 American Heart Association guidelines on RH recommend consideration of a mineralocorticoid antagonist in patients with RH on the basis of observational studies. 1 Several small studies including a post hoc analysis of ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) study showed significant lowering of BP in patients with RH by AA. 4, 15, 17 We excluded the subgroup analysis of ASCOT trial in the current meta-analysis as the definition of RH was not strictly followed. 17 A prior meta-analysis with 12 total studies included the subgroup analysis of ASCOT trial and a study with incorrect definition of RH that we excluded in the current meta-analysis. 28 Besides, we performed separate analyses for both comparative and single-arm studies for efficacy and safety outcomes. In addition, we performed separate analyses for office BP and ABPM.
Appropriate diagnosis and management of patients with RH is important as prior studies have reported that these patients have significantly worse cardiovascular outcomes compared to non-RH patients. 7, 29 These findings are important because the prevalence of RH is only expected to increase as a result of increased life expectancy and the increasing risk factors associated with RH namely obesity, sleep apnea, diabetes, and chronic kidney disease. 30 In the background of limited treatment choices for patients with RH, this metaanalysis confirms the importance of safely adding AA as a fourth line agent in patients with RH. In recently published results of an randomized controlled trial comparing renal denervation vs. intensified pharmacotherapy including spironolactone, the renal denervation could only achieve BP reduction comparable to pharmacotherapy. 31 The RH patients on AA therapy, however, will need close monitoring of their potassium levels and adverse events because higher risks of hyperkalemia and gynecomastia were observed with AA in single-arm studies although no such risk was noted in comparative studies.
Study limitations
The current meta-analysis is not without limitations. Major limitations are limited number of randomized trials, small number of patients in most of the studies, variable duration of follow-up, and limited data on adverse events. We also observed significant heterogeneity in some of the outcomes which needs to be reviewed cautiously. Inability to perform patient level analysis was another potential limitation. Nevertheless, this meta-analysis appropriately summarizes the available data from both randomized and nonrandomized studies on the efficacy and safety outcomes of AA on RH.
In conclusion, on the basis of the current meta-analysis, we conclude that the AA cause significant reduction in both office and ABPM and can be safely used in patients with RH.
SUPPLEMENTARY MATERIAL
Supplementary materials are available at American Journal of Hypertension (http://ajh.oxfordjournals.org).
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